4,663 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Aigen Investment Management LP

Aigen Investment Management LP purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,663 shares of the company’s stock, valued at approximately $395,000.

Several other hedge funds have also recently modified their holdings of the stock. FMR LLC raised its position in shares of Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after purchasing an additional 185,951 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Axsome Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock worth $81,659,000 after purchasing an additional 23,564 shares during the last quarter. Wellington Management Group LLP raised its holdings in Axsome Therapeutics by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after acquiring an additional 8,125 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Axsome Therapeutics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock valued at $27,755,000 after acquiring an additional 5,438 shares during the last quarter. Finally, Loomis Sayles & Co. L P raised its holdings in Axsome Therapeutics by 11.0% in the 3rd quarter. Loomis Sayles & Co. L P now owns 298,586 shares of the company’s stock valued at $26,834,000 after acquiring an additional 29,497 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $122.17 on Friday. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The stock has a market capitalization of $5.96 billion, a P/E ratio of -20.40 and a beta of 0.99. The company has a 50 day moving average price of $108.78 and a 200 day moving average price of $97.69. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. Equities research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have commented on AXSM. Truist Financial increased their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Axsome Therapeutics in a report on Thursday. Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $176.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Finally, Robert W. Baird increased their price objective on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the company an “outperform” rating in a report on Monday, March 3rd. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $167.36.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.